BDTX Earnings — Black Diamond Therapeutics, Inc. Common Stock Post-ER Performance | BigEarnings
BDTX — Black Diamond Therapeutics, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$2.22
Market Cap$127.2M
P/E—
52W Range$1.93 – $4.94
Next Earnings2026-08-06
About Black Diamond Therapeutics, Inc. Common Stock
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
